Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience.
Elderly
Geriatric assessment
Hodgkin lymphoma
Sarcopenia
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
31
03
2021
received:
12
12
2020
accepted:
21
05
2021
pubmed:
12
6
2021
medline:
26
11
2021
entrez:
11
6
2021
Statut:
ppublish
Résumé
Elderly classical Hodgkin lymphoma (cHL) (ecHL) is a rare disease with dismal prognosis and no standard treatment. Fitness-based approaches may help design appropriate treatments. Sarcopenia has been associated with an increased risk of treatment-related toxicities and worse survival in various solid tumours, but its impact in ecHL is unknown. The aim of this retrospective multicentre study was to investigate the prognostic role of sarcopenia in ecHL. We included newly diagnosed >64 years old cHL patients who performed a baseline comprehensive geriatric assessment and high-dose computed tomography (CT) or 18fluorine-fluorodeoxyglucose positron emission tomography/CT before any treatment. Sarcopenia was measured as skeletal muscle index (SMI, cm We included 154 patients (median age 71 years old, 76 female). The median L3-SMI was 42 cm Baseline evaluation of sarcopenia through radiological examinations performed for ecHL staging may help define a proportion of male patients with unfavourable outcome with current treatment strategies. Also the functional status evaluation could allow to identify a frail subgroup of patients with worse outcome.
Sections du résumé
BACKGROUND
Elderly classical Hodgkin lymphoma (cHL) (ecHL) is a rare disease with dismal prognosis and no standard treatment. Fitness-based approaches may help design appropriate treatments. Sarcopenia has been associated with an increased risk of treatment-related toxicities and worse survival in various solid tumours, but its impact in ecHL is unknown. The aim of this retrospective multicentre study was to investigate the prognostic role of sarcopenia in ecHL.
METHODS
We included newly diagnosed >64 years old cHL patients who performed a baseline comprehensive geriatric assessment and high-dose computed tomography (CT) or 18fluorine-fluorodeoxyglucose positron emission tomography/CT before any treatment. Sarcopenia was measured as skeletal muscle index (SMI, cm
RESULTS
We included 154 patients (median age 71 years old, 76 female). The median L3-SMI was 42 cm
CONCLUSIONS
Baseline evaluation of sarcopenia through radiological examinations performed for ecHL staging may help define a proportion of male patients with unfavourable outcome with current treatment strategies. Also the functional status evaluation could allow to identify a frail subgroup of patients with worse outcome.
Identifiants
pubmed: 34114749
doi: 10.1002/jcsm.12736
pmc: PMC8350211
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1042-1055Informations de copyright
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Leuk Lymphoma. 2019 Dec;60(12):2890-2898
pubmed: 31282794
Blood. 2012 Jan 19;119(3):692-5
pubmed: 22117038
Br J Haematol. 2016 Mar;172(6):879-88
pubmed: 26763986
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):567-576
pubmed: 27104110
Osteoporos Int. 2010 Apr;21(4):543-59
pubmed: 19779761
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Leuk Lymphoma. 2020 Dec;61(13):3209-3216
pubmed: 32705908
J Clin Oncol. 2005 Aug 1;23(22):5052-60
pubmed: 15955904
Longev Healthspan. 2014 Dec 01;3(1):9
pubmed: 25520782
BMC Geriatr. 2016 Oct 5;16(1):170
pubmed: 27716195
Adv Hematol. 2011;2011:725219
pubmed: 21197477
J Clin Oncol. 2018 Oct 20;36(30):3015-3022
pubmed: 30179569
Support Care Cancer. 2016 May;24(5):2075-2084
pubmed: 26546456
Leuk Lymphoma. 2015 Apr;56(4):921-6
pubmed: 25110825
J Clin Oncol. 2021 Apr 10;39(11):1214-1222
pubmed: 33577377
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Annu Rev Med. 2011;62:265-79
pubmed: 20731602
J Clin Oncol. 2009 Aug 10;27(23):3815-21
pubmed: 19470931
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
Leuk Lymphoma. 2014 Apr;55(4):817-23
pubmed: 23781925
Proc Nutr Soc. 2015 Nov;74(4):355-66
pubmed: 25851205
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Clin Cancer Res. 2009 Apr 15;15(8):2920-6
pubmed: 19351764
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Stat Med. 1992 Dec;11(16):2093-109
pubmed: 1293671
Cancer. 1992 Aug 15;70(4):830-4
pubmed: 1643615
J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):1042-1055
pubmed: 34114749
Leuk Lymphoma. 2014 Jan;55(1):38-43
pubmed: 23517562
Eur J Haematol. 2014 Jul;93(1):9-18
pubmed: 24520908
Ann Hematol. 2015 Dec;94(12):2043-53
pubmed: 26385388
Ann Oncol. 2004 Jan;15(1):123-8
pubmed: 14679131
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):298-304
pubmed: 27897411
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Haematologica. 1996 Sep-Oct;81(5):450-6
pubmed: 8952159
Br J Haematol. 2015 Jul;170(2):179-84
pubmed: 25891777
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
J Nutr. 1997 May;127(5 Suppl):990S-991S
pubmed: 9164280
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219